We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
- Authors
Brown, P. M.; Tzannes, S.; Nguyen, S.; White, J.; Langova, V.
- Abstract
Background: The aim of this study was to describe the use of a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol used for treatment of chemotherapy naive T-cell lymphoma patients and to describe the response rate, toxicity and disease-free interval compared historically to CHOP chemotherapy. Materials and Methods: Retrospective case study of 31 dogs with naïve T-cell lymphoma treated with a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol. Results: Thirty-one dogs with T cell lymphoma were treated. The overall response rate was 97%. Of the 30 dogs that had a response to LOPP chemotherapy, the median disease free interval was 176 days (range 0–1745 days). The median overall survival time for this study group was 323 days (range 51–1758 days). All deaths in this study were attributable to lymphoma. Conclusion: LOPP chemotherapy for T cell lymphoma is well tolerated with a low toxicity profile and an excellent overall response rate. This protocol showed minimal toxicity and comparable disease free interval and survival times for canine high grade T cell lymphoma treated with CHOP.
- Subjects
LYMPHOMAS in dogs; T cells; DRUG therapy; CANCER chemotherapy; PREDNISOLONE; VETERINARY therapeutics; TUMORS
- Publication
Veterinary & Comparative Oncology, 2018, Vol 16, Issue 1, p108
- ISSN
1476-5810
- Publication type
Article
- DOI
10.1111/vco.12318